Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

U0020000

Ubidecarenone

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Coenzyme Q10, Q-10, Ubiquinone 50, Ubiquinone-10

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C59H90O4
Numéro CAS:
Poids moléculaire :
863.34
Numéro Beilstein :
1900141
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24

Source biologique

fermentation/recombinant (yeast)

Qualité

pharmaceutical primary standard

Agence

EP

Famille d'API

ubidecarenone

Forme

solid

Fabricant/nom de marque

EDQM

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Pf

49 °C

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

O=C(C(OC)=C1OC)C(C/C=C(C)/CC/C=C(CC/C=C(CC/C=C(CC/C=C(CC/C=C(CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)\C)\C)\C)\C)\C)=C(C)C1=O

InChI

1S/C59H90O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+

Clé InChI

ACTIUHUUMQJHFO-UPTCCGCDSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Ubidecarenone, referred to as coenzyme Q, is abundantly available in human cells, with major proportions being present in vital body organs such as heart and kidneys. It plays an important role in cell metabolism owing to its significant contribution to the electron transport pathway. It is a strong antioxidant and acts as an essential enzyme catalyst in mitochondrial oxidative phosphorylation.

Application

Ubidecarenone may be used as an EP reference standard for the determination of the analyte in pharmaceutical formulations by liquid chromatography.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions
Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and (2015)
Ubidecarenone
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 8(54), 3875-3876 (2016)
Coenzyme Q10 inhibits the activation of pancreatic stellate cells through PI3K/AKT/mTOR signaling pathway
Xue R, et al.
Oncotarget, 8(54), 92300-92300 (2017)
D Orsucci et al.
Current medicinal chemistry, 18(26), 4053-4064 (2011-08-10)
Coenzyme Q10 is a small electron carrier of the respiratory chain with antioxidant properties, widely used for the treatment of mitochondrial disorders. Mitochondrial diseases are neuromuscular disorders caused by impairment of the respiratory chain and increased generation of reactive oxygen
Shirin Kalyan et al.
The Journal of clinical endocrinology and metabolism, 99(4), 1307-1313 (2014-01-16)
Nitrogen-bisphosphonates (N-BPs) are the most widely used drugs for bone fragility disorders. Long-term or high-dose N-BP use is associated with unusual serious side effects such as osteonecrosis of the jaw, musculoskeletal pain, and atypical fractures of long bones. It has

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique